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Abstract
Background: After initially falling in the face of intensified control efforts, reported rates of sexually transmitted
chlamydia in many developed countries are rising. Recent hypotheses for this phenomenon have broadly focused
on improved case finding or an increase in the prevalence. Because of many complex interactions behind the
spread of infectious diseases, dynamic models of infection transmission are an effective means to guide learning,
and assess quantitative conjectures of epidemiological processes. The objective of this paper is to bring a unique
and robust perspective to observed chlamydial patterns through analyzing surveillance data with mathematical
models of infection transmission.
Methods: This study integrated 25-year testing volume data from the Canadian province of Saskatchewan with
one susceptible-infected-treated-susceptible and three susceptible-infected-treated-removed compartmental
models. Calibration of model parameters to fit observed 25-year case notification data, after being combined with
testing records, placed constraints on model behaviour and allowed for an approximation of chlamydia prevalence
to be estimated. Model predictions were compared to observed case notification trends, and extensive sensitivity
analyses were performed to confirm the robustness of model results.
Results: Model predictions accurately mirrored historic chlamydial trends including an observed rebound in the
mid 1990s. For all models examined, the results repeatedly highlighted that increased testing volumes, rather than
changes in the sensitivity and specificity of testing technologies, sexual behaviour, or truncated immunological
responses brought about by treatment can, explain the increase in observed chlamydia case notifications.
Conclusions: Our results highlight the significant impact testing volume can have on observed incidence rates,
and that simple explanations for these observed increases appear to have been dismissed in favor of changes to
the underlying prevalence. These simple methods not only demonstrate geographic portability, but the results
reassure the public health effort towards monitoring and controlling chlamydia.
Background
With millions of new cases occurring annually, Chlamy-
dia trachomatis is the most common cause of bacterial
sexually transmitted infection (STI) worldwide [1].
Among women, the magnitude of morbidity associated
with sexually transmitted chlamydia can be staggering
[1,2]. Chronic and progressive disease due to unresolved
chlamydia infections include endometritis, salpingitis,
pelvic inflammatory disease, ectopic pregnancy [3-5],
and has also been associated with an increased risk of
human immunodeficiency virus infection and cervical
dysplasia [1]. Given the detrimental impact that chlamy-
dia infections can have on reproduction, currently
observed rates, and how best to reduce them, have been
at the forefront of national policy agendas in North
America, Europe, and Australia [5-7].
Collectively, two noticeable epidemiological profiles
among reported case rates have emerged throughout
many developed countries [3,4]. The first of these profiles
has been observed in Canada, Finland, Norway, and Swe-
den where, after initially falling in the face of intensified
control efforts, reported rates of chlamydia infections
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observed in the U.S., the U.K., and Australia where inci-
dence rates have been steadily increasing throughout
their entire reporting history [3]. Recent hypotheses for
these rising trends of chlamydia have focused on the
introduction of improved testing technologies, antimicro-
bial resistance, wide spread changes in the riskiness of
sexual practices, and arrested immunity [4] (see Table 1).
While the evidence supporting these hypotheses has been
the subject of recent debate [4,8,9], their validity remains
to be a focal point of current chlamydia research [9].
None of the hypotheses in Table 1 are mutually
exclusive, and several are likely operating simulta-
neously [4]. Therefore, understanding how these
hypotheses are contributing to the dynamics of chla-
mydia will benefit from (but not entirely depend upon)
techniques for modelling dynamic complexity. The pri-
mary advantage to using dynamical models is that they
depict explicit statements about system structure and
how the elements within the system interact [10]. As a
result, they enable valuable insights into how certain
behaviour has arisen over time [10,11]. We believe that
this methodological strength is particularly well suited
for elucidating the main drivers behind rebounding
case counts of chlamydia infections. In this article, we
discuss: one, the methodological approach we used to
construct simple mathematical models of chlamydia
transmission; two, how we were able to integrate them
with observed data; and three, how we used this
approach to, in the context of recent rebound hypoth-
eses (Table 1), parsimoniously explain the current epi-
demiological profile of chlamydia infections in the
Canadian province of Saskatchewan.
Methods
Data Sources and Trends
Saskatchewan has a population of approximately
1,014,649 people [12]. Of this number, approximately
7.7 per cent of its residents are between the ages of 15
and 19 years, 7.5% are between the ages of 20 and 24
years, and 84.8 per cent are ≥ 25 years of age. In
Saskatchewan, 13 health regions collect surveillance data
on reportable diseases, which are then reported to the
Communicable Disease Division of the Saskatchewan
Ministry of Health. Of the three-abovementioned age
groups, those aged between 15 and 24 years comprise
64 to 76 per cent of all reported chlamydia cases in Sas-
katchewan [5].
Since 1984, chlamydia infections have been a reporta-
ble infectious disease in Saskatchewan. During this time,
all reported cases of chlamydia have either been diag-
nosed based on clinical criteria (i.e., urethral discharge,
burning on urination, irritation in the distal urethra,
dysuria, abnormal vaginal discharge or menstrual bleed-
ing, post-coital bleeding, and lower abdominal pain)
[4,5], laboratory methods (i.e., culture, enzyme immu-
noassay or polymerase chain reaction), or both depend-
ing on the year.
Key, aggregated longitudinal data between 1983 and
2007 were assembled from a combination of Provincial
Health Reports, records of the Provincial Laboratory, as
well as the Public Health Agency of Canada. These data
consisted of reported chlamydia case counts, incidence
rates (per 100,000 population per year), and testing
volume. Case notifications and incidence data are publi-
cally available, and was obtained through a combination
of reviewing Public Health Reports of the Saskatchewan
Ministry of Health, and from the Public Health Agency
of Canada’s Notifiable Diseases Online website where
data gaps existed for historic years in Provincial records.
Data of testing volumes is also publically available, and
was provided to us by the Saskatchewan Ministry of
Health upon request. No formal permission was
required to use these data.
Between 1983 and 1991, chlamydia test volume data
was combined with another category of viral testing.
However, we were able to obtain documented viral test-
ing levels for several years before 1983 (i.e., 1979-1982)
from public health reports of the Saskatchewan Ministry
of Health. Using the earliest data that separated chlamy-
dia testing volumes (1991-1992) in conjunction with
records of “combined” viral testing volumes (1982-1990)
Table 1 Seven hypotheses for increasing Chlamydia rates modified from “Epidemiology of Chlamydia infection: are we
losing ground? Rekart ML, Brunham RC, 84; 87-91, copyright 2008” [4] with permission from BMJ Publishing Group,
Ltd.
H1. More false positive tests because NAAT* methods have lower specificity than culture methods.
H2. NAAT testing results in increased case detection due to better sensitivity than non-NAAT methods.
H3. NAAT testing of urine is less invasive and more acceptable, particularly among men, resulting in higher testing rates.
H4. NAAT methods allow for self-collected specimens and targeted screening among persons at high risk.
H5. Decreased chlamydial susceptibility to antimicrobials.
H6. Increased rates of unsafe sexual practices.
H7. Arrested immunity resulting from treatment with antimicrobials.
* NAAT = Nucleic Acid Amplification Test.
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between 1983 and 1990. The “combined” category
imposed an upper bound on the level of chlamydia test-
ing that could have occurred. Each of the different
imputation strategies was bounded within a narrow
defined range of possible values that converged by 1990
(not shown). Because of this asymptotic consistency, the
resultant imputed test volume data series did not affect
the overall interpretation of the results we report below.
From reported chlamydia case counts and testing
v o l u m e ,w ew e r ea l s oa b l et od e r i v eat i m es e r i e sf o r
prevalent chlamydia infection among those tested.
Two characteristics of this data gave us a unique
advantage over previous studies on chlamydia transmis-
sion: the first was a 25-year reporting history of chlamy-
dia. To our knowledge, there are few jurisdictions,
worldwide, that have access to similarly broad data; the
second was that all testing in the province has been
done by one agency (i.e., the Provincial Disease Control
Laboratory). This provided reliable testing volume (i.e.,
denominator) data over the entire reporting history.
Some of the salient trends of reported chlamydia cases
are displayed in Figure 1. This time series displays rapid
growth from 1983 to the late 1980s - a factor that was
undoubtedly fueled by the fact that chlamydia had
become a reportable infection in 1984. This was fol-
l o w e db yp r o n o u n c e dd o w n w a r dt r e n db e t w e e n1 9 8 8
and 1996. Since 1991, the province of Saskatchewan has
recorded incidence rates up to two-times higher than
national rates, and since 1997, an observable rebound
has occurred.
Model Structure and Formulation
T h em o d e l sw ee x a m i n e dp r o vided robust frameworks
for data analysis. In particular, they were developed to
integrate testing volume data, reproduce reported chla-
mydia case counts, while also seeking to understand the
general epidemiological processes underlying these time
series. Throughout this investigation, the above data
contributed to adding confidence to model assumptions
and structure. Model construction followed an iterative
process where various causal hypotheses were translated
into systems of differential equations. These equations
were then simulated to determine whether they were
capable of reproducing historical data using plausible
parameter values derived from the chlamydia literature.
Model structures were purposefully kept simple so to
focus on broad insights into the processes that have
shaped chlamydial patterns over time [13]. Through an
extensive process of testing and evaluation (see below),
several model structures were investigated. The model
presented below emerged from that process as the most
parsimonious dynamic hypothesis that adequately cap-
tured the historic patterns. However, we should note
that the results we describe below remain consistent
across the model structures we examined. Where
Figure 1 Historic trends of Chlamydia trachomatis infections in Saskatchewan and Canada between 1983 and 2007.A s t e r i s ki n d i c a t e s
when chlamydia infections became reportable in Saskatchewan (1984). Saskatchewan Incidence rates (per 100,000 population per year) are
crude rates and are calculated as the ratio of number of reported cases and the population of Saskatchewan.
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matical details of model development. However, these
details (including the other model structures examined)
are outlined in the attached Additional file 1 or are
available from the authors directly. An overview of the
presented model structure is displayed in Figure 2.
We adopted a deterministic, compartmental, suscepti-
ble-infected-treated-removed-susceptible (or SITRS) fra-
mework [14,15]. The susceptible class, S,c o n t a i n e d
those who were sexually active and could become
infected; the infected class, I, contained those who were
infectious; the treated class, T,c o n t a i n e dt h o s ew h o
either sought health care or were found by contact tra-
cing. Testing sensitivity and specificity were assumed to
r a n g eb e t w e e nt h o s eo fc e l l culture, enzyme immuno
assays, and nucleic-acid amplification testing (NAAT).
As a result, the treated class T contained both true and
false positives; these people were assumed to have been
tested, diagnosed as cases, and treated appropriately;
these individuals were also assumed to abstain from
risky sexual contact according to Public Health Agency
of Canada guidelines [5] and remain “quarantined” in
the treated class for the duration of treatment; the
removed class, R, contained those who had naturally
recovered from infection. This class also contained
those who were given a positive diagnosis and tempora-
rily reduced their sexual risk-taking behaviour after
being treated. People in the removed class were assumed
to eventually exit the sexually active population, or
return to the susceptible class as a result of waned
immunity or relapse into previous risky sexual behaviour
(Figure 2).
The primary contribution of this approach is that it
brings a unique perspective of integrating data with math-
ematical models in order to gain a novel understanding of
chlamydial patterns that have been observed between
1983 and 2007. Model structure directly incorporated data
for recorded test volumes as part of the testing assump-
tions explicitly captured by the model structure (please
refer to “Model 1” in Additional file 1). Models were then
calibrated to match case notification data. Integrating test-
ing volume into the models placed a constraint on the
Figure 2 Schematic stock and flow diagram of the susceptible-infected-treated-removed model. We adopted a deterministic,
compartmental, susceptible-infected-treated-removed-susceptible (or SITRS) framework. The susceptible class, S, contained those who were
sexually active and could become infected; the infected class, I, contained those who were infectious; the treated class, T, containing both true
and false positives; these people were assumed to have been tested, diagnosed as cases, and treated appropriately; the removed class, R,
contained those who had naturally recovered from infection, and those who were given a positive diagnosis and temporarily reduced their
sexual risk-taking behaviour after being treated. People in the removed class were assumed to eventually exit the sexually active population, or
return to the susceptible class as a result of waned immunity or relapse into previous risky sexual behaviour. Additional model structures that
were also investigated are displayed in Additional file 1.
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counts. As a result of these data constraints, we were then
able to “triangulate” an estimate of the prevalence of chla-
mydia infections in the population.
Other model structures examined the effect of treat-
ment on the development of acquired immunity in com-
bination with changes in sexual risk-taking behaviour
(see Models 3 and 4 in Additional file 1). While
acknowledging the importance of intricate biological
and epidemiological differences by gender, age, and
symptomotology our models followed the assumptions
of Hethcote and Yorke [11] and ignored their effect.
Instead, the models assume that chlamydia transmission
occurs in one uniform homogeneous population of
sexually active people. The population represented by
these models therefore consists of those individuals at
high risk, those who are efficient transmitters, as well as
their sexual contacts.
Parameter Values and Model Calibration
Initial parameter values were derived from available lit-
erature. Their values and ranges are summarized in
Table 2. Model calibration, crosschecking, and sensitiv-
ity analyses were performed using a four-step process
adapted from Van de Velde et al [16]:
1. Setting initial parameter values: Each parameter
value associated with the natural history of infection
or treatment was estimated from key epidemiological
or review articles in the available literature between
1997 and 2007. Where unavailable, parameter values
(e.g., duration of sexual activity) were taken from
modelling literature on gonorrhea infections [17,18].
Given that both gonorrhea and chlamydia are trans-
mitted by similar behaviour, we think using data
from other STIs is a reasonable assumption.
2. Sampling parameter ranges and fitting the model:
Each parameter value was associated with a range of
values found in the literature surveyed. Parameter
settings that minimized the discrepancy between the
historic reported case counts and those output by
the model, were determined by a sequence of 50
optimizations using the Powell global optimization
algorithm available in Vensim DSS for Windows
(version 5.5c). This enabled different combinations
of parameter vectors to be explored. Each optimiza-
tion used a distinct random number seed, and per-
formed approximately 1.0 × 10
6 simulations (totaling
5.0 × 10
7 simulations across all optimizations).
3. Crosschecking model fit: To build confidence in
the model results, we compared model simulations
to observed data series that were not used in step 2.
These included the reported incidence rate (per
100,000 population per year) and fraction of positive
cases among those tested.
4. Sensitivity Analysis: Each of the optimization sce-
narios identified a different point in parameter space
that offered the “best fit” to the historic data.
Because of this inherent variability present in each
optimization scenario, we performed a sensitivity
analysis based on the distribution of parameter vec-
tors produced in step 2.
Results
Model Fit and Validation
Figure 3 compares the observed historic trends in Sas-
katchewan and calibrated model simulations. In contrast
to other seminal work on modelling STI transmission
[11,17,18], a model that incorporates a “removed” state
best reproduces observed chlamydia trends (see Figure 3
and Additional file 1, Figure S4). As shown, the model
was able to accurately mirror observed temporal
changes in reported case counts (Figure 3A). These tra-
jectories also accurately reproduced the temporal
changes in the observed incidence and the proportion
positive among those tested without explicit instruction
to match these data (Figures 3B and 3C, respectively).
Table 2 Baseline parameter values used during model calibrations.
Parameter Description Value (units) References
ˆ  The mean number of susceptible individuals infected with chlamydia per year by an index case. 0.8-10
(1/year)
[27]
1/s Average duration of natural infection. 1.25* (years) [27-30]
1/s’ Average duration of infection when treated. 0.038* (years) [5]
 Diagnostic test sensitivity. 0.50-0.92 [7]
’ Diagnostic test specificity. 0.98-1.0 [7]
1/μ Average duration of sexual activity. 15
† (years) [17,18]
1/δ Average duration removed. 0.5-10
† (years) [6,21]
nI Number of infectives tested. Calculated
nS Number of susceptibles tested. Calculated
*Fixed value based on references cited; † Assumption of parameter value based on references cited.
Vickers and Osgood BMC Infectious Diseases 2010, 10:70
http://www.biomedcentral.com/1471-2334/10/70
Page 5 of 10One major advantage of this analysis was that it
allowed us to produce a triangulated estimate of the
“true” epidemiological state (i.e., the infected class I)
that underlies the observed trends. Hereafter this will
be referred to as the “actual” prevalence. As shown in
Figure 3D, the model suggests that actual prevalence
reached a maximum shortly after 1984, was in decline
between 1991 and 1996, and was followed by an upward
rebound between 1996 and 2003. It is interesting to
note that while the model suggests that a rebound in
the actual prevalence has indeed occurred, the peak of
this upward trend lies below the peak attained in the
mid 1980s. This behaviour suggests that the prevalence
is moving towards an endemic steady state by a series
of weakly damped oscillations - a familiar feature of the
types of infectious disease models we studied here [14].
When the actual prevalence is superimposed on the
observed trends in testing volumes, an obvious
divergence between 2005 and 2007 is demonstrated
(Figure 3D). Specifically, testing volume appears to be
steadily increasing, while the actual prevalence has
plateaued.
Parameter Uncertainty
The parameter sets that best fit the observed epide-
miological data produced a wide range of combina-
tions. When we accounted for variability in the
calibrated parameter values, the model’st r a j e c t o r i e sf o r
the actual prevalence of chlamydia exhibited minor
change and retained the same basic behaviour over
time (Figure 4A). Even though this model did not
explicitly simulate the efficiency of contact tracing, the
model results suggest that the level of healthcare cov-
erage (expressed as the fraction of recovering cases
recovering through treatment) rapidly increased in the
Figure 3 Comparison of model calibrations to observed trends. Calibrated numbers of (A) cases from the models compared to reported
numbers of cases in Saskatchewan. Parts (B) and (C) cross-check the model to the observed proportion positive among those tested (B), and the
reported incidence (per 100,000 population) (C). Model-generated curves in parts (A), (B), and (C) were arbitrarily chosen from 50 million
optimization simulations. Part (D) is a visual comparison of testing volume between 1983 and 2007 to the “actual” prevalence in Saskatchewan
generated by the model.
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(Figure 4B).
Discussion
Globally increasing chlamydia rates have been widely
discussed to be a result of both changes to testing tech-
nologies and changes in human sexual and social beha-
viour near the mid- to late-1990s [4,8,9]. Although
initially intuitive, the results presented here provide
evidence that such observed rebounding trends in chla-
mydia infections have resulted from a simpler set of
oscillating epidemiological processes, in particular a sig-
nificant delay in replenishing the susceptible population,
that have been operating throughout the entire history
of this infection. Taken together, our results demon-
strate that currently observed rebounding chlamydia
notifications are more likely a combined artifact of: one,
when chlamydia infections became reportable; and two,
Figure 4 Uncertainty and sensitivity analysis of model results. Parts (A) and (B) are the results of a sensitivity analysis on the “actual”
prevalence generated by the model and the fraction of infectives that have recovered via treatment, respectively. In both parts (A) and (B), the
black line represents the mean value, and the coloured bands represent the 50 (red), 75 (yellow), 95 (green), and 99 per cent (blue) confidence
intervals.
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was well-established (shortly after 1987), rather than
because of fundamental changes that have arisen
because of some of the hypotheses in Table 1 (see Addi-
tional file 1, Figure S5).
Several pieces of evidence suggest that adopting
NAAT technologies have likely had an impact on
observed chlamydia case counts. First, testing via NAAT
methods is done on urine, which is more acceptable and
easier to collect from high-risk youth and male patients
[4]; this will, ultimately, allow more tests to be collected.
Second, because of an increased sensitivity and
decreased specificity profiles compared to non-NAAT
methods, NAAT technologies allow for improved case
detection [19-21]. While the improved sensitivity and
decreased specificity profiles of NAAT methods are
likely to impact observed chlamydia case rates [8], our
models were able to reproduce observed trends without
having to account for changes in test sensitivity or spe-
cificity since their introduction (which in many parts of
Canada was between 2000 and 2001). Overall, our analy-
sis is able to reinforce previous statements that higher
testing frequency, alone, can have a significant influence
on observed rates [8,21].
Additionally, our analysis suggests the existence of a
positive feedback from testing volume that accounts for
the recent continued climb in the reported chlamydia
case counts between 2002 and 2006: a greater number
of positive tests led to more awareness of the infection,
which led to more testing being done, and still a larger
number of positive tests (Figure 3D). However, higher
rates of testing will also bring higher rates of treatment.
Higher rates of treatment appear to have led to a reduc-
tion of the underlying prevalence over time, and thus
contributed to the observed damped oscillations in the
actual prevalence. Upon reflecting on the behaviour of
the actual (model-derived) prevalence, we would also
expect that observed rates will eventually begin to pla-
teau as the prevalence among people tested begins to
approach the actual prevalence in the population at risk.
The arrested immunity hypothesis posits that early
treatment interrupts the immune response, thereby
enhancing population susceptibility to infection as peo-
ple re-enter the same sexual networks [4,22]. When we
accounted for this phenomenon in two of the alternative
model structures (Models 3 and 4 in Additional file 1),
nearly identical results were observed when compared
to a model that did not account for it (i.e., the model
represented in Figure 2). The fact that the structures of
Models 3 and 4 were able to accurately reproduce data,
after being constrained by testing volume data, suggests
that arrested immunity is very likely an important com-
ponent of the underlying dynamics of chlamydia trans-
mission. However, additional sensitivity analyses on
Models 3 and 4 (not shown) revealed that the impact of
arrested immunity at the population level may not be as
significant as previously discussed [3]. Overall, this too
seems to suggest that adverse immunological impacts of
current test-and-treat polices are not required to explain
the rebound.
Similarly, previous discussions in the literature have
also implicated rebounding chlamydia rates to be a
function of increased high-risk sexual behaviour that
has, ultimately, resulted in an increase in both on-going
and new chlamydia infections [4,6,9]. The models we
presented here captured two different aspects of beha-
viour change. These were the mean number of suscepti-
ble individuals infected with chlamydia per year by an
index case, ˆ  , and the average duration a person stayed
in the removed class, 1/δ. However, as with changes in
testing technologies and arrested immunity, our models
were able to reproduce observed trends without having
to appeal to changes in sexual risk-taking behaviour.
There are some limitations to our analysis that need
to be discussed. As with any model, the given structure
represents a simplification of reality. We chose to
develop a population-based model that is appropriate
for exploring transmission dynamics in a large popula-
tion where the infection is endemic. Therefore, we did
not evaluate the impact of network structure or the
duration of sexual partnership on our results. Although
we may have described our results at the level of the
individual, models of this type do not capture events
that occur at the individual level. As a result, the models
we present here will offer poor resolution for investigat-
ing network-based interventions. Despite this, these
types of models are still capable of providing broad-level
insights into historic and current epidemiology at the
level of the population [23,24], and are able to shed
light on specific questions in a way that alternative mod-
els, including human intuition and traditional epidemiol-
ogy, do not.
M o d e l sa r eo n l ya su s e f u la st h ed a t aa v a i l a b l et o
inform them. Although our simple models contain
many plausible relations that have some precedent in
previous epidemiological observations, they were devel-
oped and calibrated in the absence of some important
numerical data (e.g., data stratified by age and gender).
Despite this simplification of reality, we do not think
that stratifying the model by age or gender would have
benefited the results presented here. This is largely
because of inadequate provincial data to calibrate age
and gender specific mixing parameters. In our opinion,
calibrating a stratified model in the absence of such data
w o u l dh a v es u f f e r e df r o mo v e r f i t t i n g .R e g a r d l e s so f
these simplifying assumptions, one of the strengths of
this analysis is that integrating surveillance data with
dynamic models of chlamydia transmission allowed us
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data that has been largely criticized for lacking it [8,9].
More notably, these analyses have also highlighted how,
o n c eas u r v e i l l a n c es y s t e mi s well established (which in
Saskatchewan was near 1987), and given a concerted
effort to identify as many cases as possible, surveillance
data (e.g., time series of testing volume) can mimic the
underlying prevalence of infection (see Figure 3D and
Additional file 1, Figure S5).
Although extant data limitations ruled out construct-
ing a stratified model, two considerations give studying
demographic heterogeneity priority for future work.
First, having been able to explain the rebound in
observed case notifications as a function of testing
volume, collection of more detailed data could highlight
contextual epidemiological differences among those
being tested for chlamydia. Second, for these models to
offer value in assessing intervention tradeoffs, it will be
important to account for these population heterogene-
ities in the model structure. We are currently drawing
on more-detailed data from a sub-provincial level (e.g.,
changes in contact rates, gender distribution amongst
tested cases, the age distributions of contacts, rates of
pelvic inflammatory disease, and changes in the social
marketing of healthcare services over time) to expand
the insights of the current analyses.
Conclusions
With 25 years of data corresponding to over 804,000
tests and 69,000 cases this is likely one of the largest
retrospective analyses on genital chlamydia. To help
clarify the dynamic mechanisms underlying observed
trends, the models presented here draw upon available
indicators within existing data and integrate several
cause-and-effect hypotheses. As a result, this has
allowed us to critically examine the appropriateness of
several key rebound hypotheses.
The primary aim of this study was to parsimoniously
explain the recently observed rebound epidemiological
profile of chlamydia since it became a reportable infec-
tion in the Canadian Province of Saskatchewan. By com-
bining dynamic models with testing volume data to
reproduce observed surveillance data, our results high-
light the significant impact testing volume can have on
observed case counts. The results of this study also illus-
trate the usefulness of our methods for deriving estimates
of infection prevalence from freely available surveillance
d a t a .O v e r a l l ,t h e yp r o v i d ea viable explanation for
reported trends that appears to have been overlooked or
dismissed in favor of hypotheses involving large-scale,
aberrant changes to the underlying prevalence [21].
The calibrated models presented here offer value as
tools for improving our understanding of chlamydia epi-
demiology. With some structural modification and
additional data, they will be useful for examining how
current trends might behave into the future under a
variety of control scenarios. For example, they may be
extended to explore the dynamics of introducing various
candidate control policies, such as a nationally dedicated
proactive screening program [6] or expedited partner
therapy [25,26]. It bears emphasizing that while we have
presented results from a single province with an excep-
tionally long record of chlamydia data, our methodologi-
cal approach is both straightforward and general.
Moreover, these methods offer geographic portability
that can help inform the public health efforts in other
contexts that collect similar information to that used
here. Most importantly, these results reassure the public
health effort towards monitoring and controlling
chlamydia.
Additional file 1: Additional Model Structures and Supporting
Information. This file contains specifics of the mathematical structure, as
well as some additional results of the models discussed in the main text.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2334-10-
70-S1.DOC]
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